PharmaCyte Biotech, Inc. — Investor Relations & Filings
Filings indexed
452
across all filing types
Latest filing
2024-05-30
Director's Dealing
Country
US
United States of America
Listing
US
PMCB
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cellular therapies for cancer and diabetes. The company's core platform is its proprietary Cell-in-a-Box® technology, a cellulose-based live-cell encapsulation system. This technology involves encapsulating genetically engineered living cells that can produce and deliver therapeutic agents in a targeted manner when implanted in the body. The primary application under development is for the treatment of locally advanced, inoperable pancreatic cancer and other solid tumors, where the encapsulated cells are designed to convert an inactive chemotherapy drug into its active form at the tumor site.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Director's Dealing 2024 | 2024-05-30 | English | |
| SCHEDULE 13D | 2024-05-30 | English | |
| FORM 8-K | 2024-05-23 | English | |
| FORM 8-K | 2024-05-01 | English | |
| DEFINITIVE PROXY STATEMENT | 2024-03-27 | English | |
| ANNUAL REPORT | 2024-03-27 | English |
Browse filings by year
26 years- 2026 3 filings
- 2025 31 filings
- 2024 20 filings
- 2023 44 filings
- 2022 50 filings
- 2021 41 filings
- 2020 10 filings
- 2019 9 filings
- 2018 7 filings
- 2017 14 filings
- 2016 17 filings
- 2015 12 filings
- 2014 35 filings
- 2013 13 filings
- 2012 16 filings
- 2011 34 filings
- 2010 16 filings
- 2009 18 filings
- 2008 4 filings
- 2007 8 filings
- 2006 8 filings
- 2005 14 filings
- 2004 19 filings
- 2003 5 filings
- 2002 3 filings
- 2001 1 filing
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
9 filings
| |||||
| 11460000 | Director's Dealing 2024 | 2024-05-30 | English | ||
| 11460003 | SCHEDULE 13D | 2024-05-30 | English | ||
| 11460002 | FORM 8-K | 2024-05-23 | English | ||
| 11460001 | FORM 8-K | 2024-05-01 | English | ||
| 11460004 | DEFINITIVE PROXY STATEMENT | 2024-03-27 | English | ||
| 11460007 | ANNUAL REPORT | 2024-03-27 | English | ||
| 11460006 | FORM 10-Q FOR JAN 2024 | 2024-03-18 | English | ||
| 11460005 | Major Shareholding Notification 2024 | 2024-02-14 | English | ||
| 11460008 | AMENDMENT NO. 3 TO SCHEDULE 13G | 2024-02-06 | English | ||
|
2023
6 filings
| |||||
| 11460009 | FORM 10-Q FOR OCTOBER 2023 | 2023-12-15 | English | ||
| 11460010 | Director's Dealing 2023 | 2023-11-28 | English | ||
| 11460012 | FORM 8-K | 2023-11-24 | English | ||
| 11460011 | Director's Dealing 2023 | 2023-11-22 | English | ||
| 11460013 | Director's Dealing 2023 | 2023-11-22 | English | ||
| 11460014 | Director's Dealing 2023 | 2023-11-22 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
PharmaCyte Biotech, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35351/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35351 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35351 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35351 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35351}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PharmaCyte Biotech, Inc. (id: 35351)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.